ArticleChemistry & biodiversity2026
Computational Analysis of Balanites aegyptiaca Phytochemicals as Inhibitors of Human Pancreatic α-Amylase.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Computational Analysis of Balanites aegyptiaca Phytochemicals as Inhibitors of Human Pancreatic α-Amylase.Chemistry & biodiversity · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Balanites aegyptiaca (BA) is a plant of paramount potential for the management of diabetes mellitus. The study investigates in silico studies of natural library compounds including that from BA with the assistance of network pharmacology. Balanitesin (compound 1) exhibited the highest docking score and binding free energy (∆G) values of -14.406 and -125.47 kcal/mol, respectively, and SN0224203 (compound 9) exhibited the docking score of -13.019 kcal/mol and binding free energy of -128.41 kcal/mol. These were found to be the most potential α-amylase inhibitor out of the phytoconstituents of BA, whereas the standard compound exhibited the docking score of -12.500 kcal/mol and ∆G value of -81.275 kcal/mol. The network pharmacology results also showed that SN0224203 might act as an α-amylase inhibitor, it was found to be associated with various genes like GCK, VDCC, PIK3, and mTOR and Type II diabetes mellitus pathway. The MDS results showed that the binding of SN0224203 with α-amylase was more stable as vivid from 50 to 300 ns simulation. Genes. Our results suggest that the compounds of BA were found to be potent against α-amylase. The findings are promising and suggest further in-vitro and in-vivo validation studies of the potent compounds from BA for better diabetes management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.